Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease

Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease

Bibliographic Details
Main Authors:	Bekker, P, Velde, A, Pronk, I, Keshav, S, Hommes, D, Hanauer, S, Ungashe, S, Zheng, W, Wright, K, Schall, T
Format:	Conference item
Published:	2007

Similar Items

Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
by: Keshav, S, et al.
Published: (2007)

PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
by: Bekker, P, et al.
Published: (2009)

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
by: Keshav, S, et al.
Published: (2009)

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
by: Keshav, S, et al.
Published: (2007)

Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
by: Bekker, P, et al.
Published: (2008)

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
by: Walters, M, et al.
Published: (2010)

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
by: Ungashe, S, et al.
Published: (2008)

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
by: Satish Keshav, et al.
Published: (2013-01-01)

Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease
by: Bekker, P, et al.
Published: (2008)

Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
by: Bekker, P, et al.
Published: (2008)

Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease
by: Bekker, P, et al.
Published: (2007)

Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis
by: Wei, Z, et al.
Published: (2005)

Expression of CCR8 and CCX-CKR on Basophils in Chronic Urticaria Is Amplified by IgE-Mediated Activation
by: Ewa A. Bartko, et al.
Published: (2023-05-01)

Systematic Assessment of Chemokine Signaling at Chemokine Receptors CCR4, CCR7 and CCR10
by: Herman D. Lim, et al.
Published: (2021-04-01)

Antagonist of chemokine receptors CCR1 and CCR3
by: Ammit Alaina, et al.
Published: (2000-11-01)

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands
by: Jan Korbecki, et al.
Published: (2020-10-01)

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
by: Daniel Clark Files, et al.
Published: (2022-06-01)

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.
by: Kathleen M C Sullivan, et al.
Published: (2023-01-01)

Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5
by: Hui Zhang, et al.
Published: (2021-07-01)

CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.
by: Wendt, E, et al.
Published: (2015)

Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice.
by: Rodrigo Guabiraba, et al.
Published: (2010-01-01)

Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3
by: Zhehua Shao, et al.
Published: (2022-05-01)

Identification and Expression Profiling Analysis of the Cation/Ca2+ Exchanger (CCX) Gene Family: Overexpression of SlCCX1-LIKE Regulates the Leaf Senescence in Tomato Flowering Phase
by: Jiao Li, et al.
Published: (2021-06-01)

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
by: Pirow Bekker, et al.
Published: (2016-01-01)

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
by: Pirow Bekker, et al.
Published: (2019-01-01)

Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B
by: Frederik Fabian Feigl, et al.
Published: (2023-02-01)

Expression and function of the chemokine receptor CCR7 in thyroid carcinomas.
by: Sancho, M, et al.
Published: (2006)

The CCR2/MCP-1 Chemokine Pathway and Lung Adenocarcinoma
by: Payal Mittal, et al.
Published: (2020-12-01)

Chemokine Receptor-Targeted Therapies: Special Case for CCR8
by: Bernhard Moser
Published: (2022-01-01)

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4
by: Jan Korbecki, et al.
Published: (2020-11-01)

A systemically-administered small molecule antagonist of CCR9 acts as a tissue-selective inhibitor of lymphocyte trafficking.
by: Noah J Tubo, et al.
Published: (2012-01-01)

The chemokine receptor CCR5: multi-faceted hook for HIV-1
by: Natacha Faivre, et al.
Published: (2024-01-01)

Structural basis of dimerization of chemokine receptors CCR5 and CXCR4
by: Daniele Di Marino, et al.
Published: (2023-10-01)

The Chemokine Receptor CCR1 Mediates Microglia Stimulated Glioma Invasion
by: Nazende Zeren, et al.
Published: (2023-03-01)

In Silico Identification of Cholesterol Binding Motifs in the Chemokine Receptor CCR3
by: Evan van Aalst, et al.
Published: (2021-07-01)

Chemokine receptor CCR3 is important for migration of mast cells in neurofibroma
by: Wei-Chun Tai, et al.
Published: (2010-12-01)

Intragenus (Homo) variation in a chemokine receptor gene (CCR5).
by: Kara C Hoover
Published: (2018-01-01)

Screening of chemokine receptor CCR4 antagonists by capillary zone electrophoresis
by: Zhe Sun, et al.
Published: (2011-11-01)

Association of chemokine receptor gene (<it>CCR2-CCR5</it>) haplotypes with acquisition and control of HIV-1 infection in Zambians
by: Hunter Eric, et al.
Published: (2011-03-01)

Chemokines and myeloid cell recruitment.
by: Greaves, D, et al.
Published: (2000)